Anti-PCSK9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (Mab) are novel, potent lipid-lowering drugs. They demonstrated to improve the lipid profile in high cardiovascular risk patients. Anti-PCSK9 Mab inhibit the targeted low-density lipoprotein (LDL)-receptor degradation induced by PCSK9 protein and are able to reduce LDL cholesterol (LDL-C) levels on top of conventional lipid-lowering therapy. Though these drugs proved to be very safe in the short-term, little is known about the possible long-term effects, due to the short period of their marketing. The genetic low cholesterol syndromes (LCS) represent the natural models of the lipid-lowering anti-PCSK9 therapy, and a valuable opportunity to predict the long-term effects of these drugs. By looking at the clinical features of such models, we could be able to foresee possible drug-induced side effects. In the present review, the correspondences and discordances between the side effects of anti-PCSK9 therapy and the corresponding LCS models will be examined in the attempt to forecast possible long-term consequences of these novel lipid-lowering agents.
Introduction
Anti-proprotein convertase subtilisin kexin 9 (anti-PCSK9) monoclonal antibodies (Mab) are novel lipid-lowering drugs that have proven to be powerful in reducing low-density lipoprotein (LDL) cholesterol (LDL-C) on top of conventional therapy, and also to be safe in the short terms of clinical trials, as well as in the observation period of the trials extension. Nevertheless, their novelty is also cause of concerns. All the available safety data were obtained during the phase III trials and over the few years of marketing. As a result, data on drug-related long-term effects and on the effects of the prolonged very low levels of cholesterol achieved are still required.
Life-long low levels of cholesterol characterize low cholesterol syndromes (LCS), a group of heterogeneous genetic conditions in which low plasma cholesterol levels are inherited and maintained by mutations of genes connected to the lipid metabolism, either regarding lipoprotein(lp) synthesis or lp catabolism. 1 It is noteworthy that the anti-PCSK9 strategy mimics a particular LCS in which plasma PCSK9 levels are reduced, so that the pharmacological effects of these drugs resemble the phenotypic presentation of the corresponding LCS. 1 It must be noticed that genetic models are characterized by life-long exposition to low levels of cholesterol, while the lipid-lowering effects of drugs are transient, affected by several factors and often discontinuous, so that a perfect matching of these two conditions is not to be expected. Taking advantage on the natural models of the LCS, the present review speculates on the effects that are likely to occur due to long expositions to these novel potent lipid-lowering drugs. The data obtained by these novel drugs will be compared with the corresponding genetic models in the attempt to highlight similarities and discordances between the pharmacological effects of the drugs and the clinical features of the genetic models. Pharmacological long-terms effects will be postulated through the examination of the elderly carriers of LCS. The considered LCS and lipid lowering therapies are summarized in Table 1 .
Anti-PCSK9 monoclonal antibodies (Mab)
These lipid-lowering agents have been developed with the aim of reducing the circulating levels of the PCSK9, the protein product of the PCSK9 gene. Three Mab have been developed up to the phase III trial: evolocumab, alirocumab, and bococizumab, but only the first two progressed to marketing.
Evolocumab and alirocumab are fully human antibodies, while bococizumab is 'humanized', meaning that it contains a small amount of murine aminoacid sequences. This murine content likely determined the stimulation of the immune response in the treated patients, 2 with appearance in the plasma of neutralizing antibodies that undermined the efficacy of bococizumab therapy over the weeks of the trials. 2 Evolocumab was realized as a dimeric IgG2 Mab, while alirocumab as a monomeric IgG1 Mab. The main consequence of the different choice of Mab architecture is the Mab half-life. Evolocumab is cleared more efficiently from the circulation, with a half-life of 11-17 days, 3 requiring a biweekly administration to maintain its therapeutic cholesterol-lowering effect, while alirocumab showed a longer half-life of 17-20 days, 4 so that it can be administered either biweekly or monthly. Concomitant administration of statins decreases the Mab half-lives because an additional amount of PCSK9 protein is supplied to the antigen-antibody reaction. 3, 4 Both Mab showed similar distribution volume upon subcutaneous administration. The value of 3.2-3.5 L guarantees that the spillover from plasma is negligible, limiting the action of the drugs to the compartments accessible from circulation. PCSK9 is a peculiar representative of the PCSK protein class. Its structure differs for the presence of an annexin-like C-terminal domain and it shows unusual regulating properties. 5 The role of PCSK9 as key regulator of cholesterol metabolism emerged from the genetic analysis of families affected by autosomal dominant hypercholesterolaemia (ADH) that resulted orphan of mutations in LDLR and APOB genes. 6 The first kindred described was analysed by parametric linkage analyses, and a missense mutation in PCSK9 demonstrated to segregate with the ADH trait. 6 Further studies elucidated the role of PCSK9 in regulating the cholesterol metabolism. 7 The PCSK9 protein is produced in several cell types, included neurons and smooth muscle cells. 8 In the liver, intracellular PCSK9 is auto-cleaved before secretion, and the resulting 13kDa terminal fragment binds to the main protein body. Active PCSK9 can be inactivated by circulating proteases, as furin. 5 Active PCSK9 binds the LDLreceptor (LDLR) creating a complex, together with a LDL particle, that is internalized by generation of clathrin-coated pits that are converted to early endosomes. 5 PCSK9 is involved in the sorting process of the endosome content. LDLR is known to recycle several times to the cell surface before degradation, while the lipoprotein remains are directed to the lysosomal compartment for recovery of protein and lipid content. 8 The PCSK9 acts as a tag that addresses the LDLR to the lysosomal compartment for degradation, halting its recycling process. As a consequence, the number of LDLR molecules on cell surface is reduced and circulating LDL-C levels increase. 7, 8 The mechanistic studies identified PCSK9 as a promising drug target for hypercholesterolaemia because of some considerations: (i) the reduction of PCSK9 activity was found to be related to low cholesterol levels, (ii) PCSK9 proved to work as a circulating protein with stable plasma levels, and (iii) both animal models and patients with PCSK9 'loss of function' (LOF) mutations remained healthy. The Mab strategy was then setup and the first phase II trials started just a few years after the discovery of PCSK9.
The anti-PCSK9 Mab trials
Results of several randomized controlled trials with evolocumab, alirocumab, and bococizumab have been published so far. The detailed list of reviewed trials is presented in Supplementary material online, Table S1 .
Alirocumab presented a trial program including about 23 000 patients from different categories: (i) patients at high cardiovascular (CV) risk, either affected by myocardial infarction, stroke, type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), as in the COMBO I and II, OPTIONS CHOICE I and II, and the LONG TERM extension trials, while the OUTCOMES study included about 18 000 patients with recent CV events; (ii) patients affected by FH, as in the FHI, FHII, and the HIGH FH trials, and (iii) patients in monotherapy, often intolerant to statin treatment, as in the MONO and the ALTERNATIVE trials. Regarding high risk patients, alirocumab reduced LDL-C by 49 .5% (52 weeks) in COMBO trials on top of maximal tolerated statin therapy. 9 LDL-C was reduced by 44 to 54% in the OPTION I trial, according to the background therapy, and by 36.3 to 50.6% in the OPTION II trial. 9 A similar effect was reported in the ODYSSEY LONG TERM trial (52.4% reduction at 78 weeks). 9 Regarding FH patients, alirocumab reduced LDL-C by 51 .8%, 52 .1%, and 45.7% in the FH I, FH II, and HIGH FH trials, similar to the 54.8% obtained in monotherapy in the statin intolerant patients of the ALTERNATIVE trial. 9 Taken together, the results suggest a sustained LDL-C reduction of 50-60% according to baseline statin therapy and irrespective of comorbidities (diabetes, CKD). Evolocumab developed a similar program, called PROFICIO, in similar categories of patients, with a total of about 30 000 patients enrolled. The LAPLACE 2 trial was developed on Japanese high risk patients, as the YUKAWA-2 trial, while RUTHERFORD-2 was aimed to treat FH patients. TESLA was a trial dedicated to hoFH patients. MENDEL-2, GAUSS-2, and GAUSS-3 trials were dedicated to patients in monotherapy, mainly intolerant to statins. The FOURIER trial included 22 500 patients at high risk with CV disease, and it was the first trial powered enough to demonstrate that the reduction of LDL-C cholesterol via PCSK9 inhibition was able to reduce incident CV events. The long-term trial OSLER-2 was completed, while the TAUSSIG trial is still ongoing.
Regarding high risk patients, evolocumab reduced LDL-C by 68.3 to 76.3% in the LAPLACE-2 trial according to baseline statin therapy, and by 74.9 to 75.9% in the YUKAWA-2 trial. 9 Regarding the FH patients, LDL-C was reduced by 61 .3% in heterozygous FH with biweekly administration of the MAb, and by 23.1% in the homozygous patients of the TESLA-B trial. 9 Both MENDEL and GAUSS-2 reduced LDL-C by 56-57% (biweekly schedule). 9 The OSLER-2 trial reported a LDL-C reduction of 61%. 9 Taken together these results show that evolocumab has an efficacy profile similar to alirocumab, with LDL-C reduction in the 50-60% range according to baseline therapy. Bococizumab produced the SPIRE program, with six trials enrolling about 4300 patients. Some trials were dedicated to high risk patients, as the SPIRE HR, SPIRE I and SPIRE 2, while the SPIRE-HF trial included also FH patients. The trials failed to maintain a sustained reduction of LDL-C due to the development of neutralizing anti-drug antibodies (ADA). The pooled data showed that the LDL lowering effect of bococizumab decreased progressively to the increase of the ADA titre, observed in about half of the patients. 2 Nevertheless, bococizumab reduced LDL-C roughly by 50% in those who did not present circulating ADA. Bococizumab development has been stopped. The relative reductions of LDL-C levels shown in the trials are important to estimate the expected reduction of CV events. Nevertheless, the
lowest absolute LDL-C levels reached in the trials, more than relative reductions, have to be taken into account to understand the consequences of the lipid-lowering effects due to anti-PCSK9 Mab, since most of the feared effects of Mab are related to the low absolute LDL-C levels observed. Figure 1 shows the average levels of LDL-C observed in the MAb arm in the relative trials, in comparison with the LDL-C levels characteristic of a FHBL cohort. 10 The low cholesterol syndromes Familial hypobetalipoproteinaemia due to APOB defects Familial hypobetalipoproteinaemia 1 (FHBL-1, OMIM #615558) is caused by mutations of APOB. This gene encodes for the apolipoprotein B (ApoB), the main apolipoprotein of all lp with the exception of HDL. 1 ApoB is expressed in two forms: the apoB100 (meaning that the full mRNA is translated to protein) expressed by the liver, and the apoB48, expressing only the 48% of the complete protein. This short isoform is produced in the intestine 1 by a dedicated editing enzyme, the 'apolipoprotein B mRNA editing enzyme catalytic polypeptide 1' (apoBEC1) that introduces a stop codon in the base at position 6666 of the APOB mRNA. 1 Most of the APOB mutations responsible for FHBL-1 encode for truncated apoB isoforms that are named as percent of the full apoB100 (1). Few missense mutations encode for aminoacid substitutions (Ala31Phe, Arg463Trp, Leu343Val) able to impair the cellular lipoprotein assembly by interfering with the microsomal triglyceride (TG) transfer protein (MTTP). 11, 12 In both cases the lipoprotein assembly is impaired, causing lipid accumulation within the cells, as shown in Figure  2A . Liver fat accumulation is the main feature of heterozygous FHBL-1, and it represents a relevant clinical issue, since fatty liver (FL) is able to evolve to non-alcoholic steato-hepatitis (NASH) and even to liver cancer, sometimes without any other genetic or environmental condition that could explain the progression. 13 Though insulin resistance (IR) is known to affect the degree of FL in FHBL-1, 14 it is not a necessary condition for the generation of lipid accumulation. 15 APOB mutations shorter than apoB48 and missense mutations determine also a condition of 'intestinal steatosis', 12, 16 whose clinical significance is still uncertain. While LDL-C levels show a mean value of 1 mmol/L in heterozygous FHBL-1 (hetFHBL-1), 10 Pitavastatin did not increase diabetes risk. 38 The 'YY' labels express a severe expression of the clinical features. 
Familial combined hypolipoproteinaemia due to ANGPTL3 defects
This defect is also known as FHBL-2 (OMIM #605019). FHBL-2 was first identified by Musunuru et al. 17 in a kindred that presented a dominant segregation of a genetic trait characterized by reduced levels of apoBand apoAI-containing lipoproteins, resulting in low levels of plasma total cholesterol (TC), LDL-C, HDL cholesterol (HDL-C), and TG. Two nonsense mutations of ANGPTL3 were identified by next generation exome analysis (NGES). The mutations encoded for two truncated ANGPTL3 isoforms, p.Ser17Ter and p.E129Ter. 17 A formal prevalence study was conducted in American and Italian cohorts of low cholesterol subjects, and the results showed that FHBL-2 is more prevalent than FHBL-1 in hypobetalipoproteinaemia if HDL-C levels were <20th percentile. 18 The analysis of a large community of FHBL-2 subjects identified in a small Italian village demonstrated that FHBL-2, differently from FHBL-1, is a recessive condition, though also some heterozygous subject sporadically presented low levels of TC or TG.
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ANGPTL3 protein is secreted in the plasma by the liver 20 and works in conjunction with ANGPTL8 and ANGPTL4 as an inhibitor of the lipoprotein lipase (LPL). 21 The lack of ANGPTL3 function increases the LPL activity, so that TG-rich lipoproteins (TRL) are catabolized more efficiently, resulting in lower circulating cholesterol and TG levels. 22 The effect of ANGPTL3 disruption on HDL-C levels is not due to the increase of LPL activity, that would increase HDL-C levels, but to the simultaneous increase of endothelial lipase activity ( Figure 2B ).
Familial hypobetalipoproteinaemia due to PCSK9 defects
According to the physiology of PCSK9 protein, it is expected that a PCSK9 mutation determining a gain of protein function (GOF) be required to develop hypercholesterolaemia, via the increase of the LDLR degradation rate. 23 On the other side of the mutational spectrum, LOF PCSK9 mutations are expected to increase the number of LDLR on cell surface, determining low circulating LDL-C levels. According to this hypothesis, a first subject with hypobetalipoproteinaemia of African-American descent was soon identified after PCSK9 discovery, 24 followed by the first subject of Caucasian origin. 25 Since then, other PCSK9 LOF mutations responsible for FHBL were identified, The LCS model of PCSK9 inhibition by monoclonal antibodies (Mab)
The administration of a single dose of anti-PCSK9 Mab demonstrated a sudden drop of plasma PCSK9 levels, with corresponding decrease of LDL-C levels up to a 60% reduction of baseline levels. 9 ,26 PCSK9 levels slowly returned to baseline, as well as LDL-C levels, in about 15 days. 26 The lipid-lowering effect is then related to the reduction of circulating PCSK9. The natural model of the anti-PCSK9 Mab therapy is then represented by a genetic condition of FHBL in which circulating PCSK9 levels are reduced due to a PCSK9 LOF mutation. As mentioned earlier, the absolute LDL-C levels reached in the trials are the first element to take into account to drive the choice of the correct genetic model of LCS for the purpose of the present review. As shown in Figure 1 , the data from the published trials resulted in average LDL-C levels in the range of 0.5 to 1 mmol/L in the Mab-treatment arms. Higher LDL-C average values were reached in trials enrolling ADH patients, while lower levels were reached in trials enrolling only high risk patients, as subjects with previous CV events in secondary prevention. The other element to take into account in the choice of the correct LCS model is the different effect on LDL-C levels exerted by different PCSK9 variants. A first set of PCSK9 variants is composed of rare variants, as the p.Arg46Leu (R46L), that only slightly affect LDL-C levels both in heterozygous and in homozygous status. 27, 28 Though valuable data can be obtained by this model because of its relatively high prevalence in the population, 28 nevertheless the model cannot be considered congruent with the trials data in terms of absolute LDL-C levels achieved, since LDL-C values determined by the R46L variant resulted in the range of 2 mmol/L, even in homozygous condition, 27,28 much higher than those observed in the trials. The correct model is then represented by the rare cases of FHBL due to PCSK9 LOF mutations, determining LDL-C levels comparable with those observed in the trials, both in heterozygous and homozygous status. Cohen et al. 27 identified the PCSK9 p.Tyr142Ter (Y142X), a non-sense mutation able, in homozygosis, to lower the LDL-C up to 1.18 DeltaR97/Y142X showed LDL-C levels as low as 0.36 mmol/L. All the PCSK9 variants carriers were described in apparent good health. Our group identified a kindred harbouring a non-sense PCSK9 mutation, p.Ala68fsLeu82X. 25 The same mutation was found in a cohort of subjects with LDL-C levels below the 5th percentile of the reference population. 25 The heterozygous carriers showed average LDL-C levels of 32 screened for PCSK9 variants in the low/high cholesterol tails of the Dallas Heart Study distribution and found that R46L was detected in both tails. Still the LDL-C average levels of R46L carriers was significantly lower that the general population. The carriers of PCSK9 variants were also investigated for liver fat content by proton magnetic resonance spectroscopy, and all the groups showed average content below the 5% of the liver volume, considering both subjects with non-sense mutations (Y142X or p.Cys679X) and carriers of the more common R46L variants. 32 Altogether examined, the publications reporting carriers of PCSK9 mutations showed that these subjects are in relative good health.
Low cholesterol levels and the risk of fatty liver
Genetic LCS are characterized by FL. This association has been demonstrated both in the clinical setting 1, 10 and by 'in vitro' cellular models of FHBL. 10 It is to notice that most of the observations of FHBL cases were produced in a period in which APOB was identified as the only gene responsible for FHBL. More than 70% of the subjects expressing truncated apoB100 isoforms showed to be affected by FL. 10 FL was confirmed by magnetic resonance spectroscopy in early studies 33 and confirmed in later reports. 1 FL of FHBL subjects is not caused by IR, as demonstrated by studies that measured IR both by euglicemic clamp 14 and by indirect measurements, as the HOMA index. 15 The bulk of evidence demonstrated that FL develops because of apoB secretion impairment, but that IR is able to modulate the degree of fat accumulation in liver and even intestine 13 FL due to IR is known to evolve to steato-hepatitis (NASH) and liver cirrhosis in a small percentage of cases, and it has been questioned whether FL is able to determine cirrhosis in FHBL. Different reports described progression to NASH in FHBL, either in presence or in absence 1,10 of precipitating factors. Our group described a kindred carrying an apoB truncated isoform in which FL, liver cirrhosis, and liver cancer segregated with the APOB mutation. 13 The study of genetic variants by next-generation whole exome sequencing did not identify any exomic mutation in any other gene that could explain the recurrence of multiple liver cancers in the same family, suggesting that also FL due to impaired lipoprotein production is able to progress to liver cirrhosis. It is then possible that any drug be able to impair apoB production in the liver, as it Anti-PCSK9 monoclonal antibodies vs. low cholesterol syndromes happens for lomitapide 34 or mipomersen, 35 erase could be responsible for potentially evolving FL. PCSK9 mutations causing LCS have not been linked to FL in any of the mentioned reports published so far, though data regarding PCSK9 LOF mutations are still scarce. In regard to the more common PCSK9 variants, namely R46L, the large cohort from mentioned paper of Kotowski et al. 32 did not show any association between PCSK9 function and FL. These data are consistent with the safety data from the trials with PCSK9 inhibitors that did not report an excess of FL in patients assuming anti-PCSK9 Mab in spite of the very low levels of LDL-C achieved. It is possible that the short duration of the trials might have limited the strength of the conclusions, but it is noteworthy that the short observation period in the lomitapide trials was sufficient to observe erase reversible FL (average 7% of liver content) developing in treated patients, 34 suggesting that a strong steatogenic effect of anti-PCSK9 Mab might have been detected also in the Mab trials. Therapeutic inhibition of PCSK9 does not seem correlated with the development of FL. Figure 2 shows the roles of LCS and lipid-lowering drugs in determining FL; panels A and B show the hepatic and endothelial mechanisms, respectively.
Low cholesterol levels and the risk of diabetes
Statins increase the risk of developing T2DM. Preliminary results from the JUPITER trial showed that patients on rosuvastatin therapy develop new cases of diabetes. 36 The diabetogenic effect of statins is more evident for powerful statins, particularly for higher dosages, and it seems more evident for lipophylic statins (simvastatin, atorvastatin) in comparison with the hydrophilic statin pravastatin. 37 Rosuvastatin resulted in diabetogenic in spite of its hydrophilicity, probably because of its high potency and affinity for the target. 37 Statins then show different diabetogenic properties, and pitavastatin, the last statin released, seems not able to increase notably the risk of diabetes, probably because of a claimed beneficial action on the adiponectin/leptin balance. 38 A current line of investigation suggests that any deviation from cholesterol homeostasis exerts opposite effects on the risk of diabetes. Hydroxyl-methyl-glutaryl coenzyme A reductase (HMG-CoA-R), the product of the HMGCR gene, is the target of the statin therapy, and it has been investigated by functional polymorphism analysis. The rs17238484 SNP of the HMGCR gene was demonstrated to reduce the enzyme activity and showed a parallel increase of diabetes prevalence in carriers of one of two rare variants, showing a clear gene-dose effect. 39 Interestingly, the carriers of this variant presented also higher BMI, suggesting that the mechanism determining diabetes was mediated by IR. It is then likely that statins, or any condition that inhibits of HMG-CoA-R, are able to fuel a diabetogenic effect.
On the other side, genetic conditions characterized by high cholesterol levels are characterized by a low prevalence of diabetes. A cohort of 25 137 patients affected by familial hypercholesterolaemia showed a prevalence of diabetes as low as 1.75%, 40 independently from the gene that caused the disease, either LDLR or APOB.
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Taken together, these data seem to indicate that plasma cholesterol levels and risk of diabetes are inversely correlated, raising the suspicion that all conditions determining low cholesterol levels, either by genetic or environmental actions, might be related to an increase of diabetes prevalence. A confirmation of this hypothesis might come from the demonstration that low cholesterol syndromes are characterized by an increased prevalence of diabetes. A recent meta-analysis evaluated a series of SNPs in different genes that are known to slightly reduce LDL-C levels. 41 All the subjects that carried rare variants of these SNPs showed a low prevalence of CV events, as expected in subjects that maintained life-long slightly low LDL-C levels, but they also showed a greater risk of prevalent diabetes. The effect was maximal for HMGCR (rs12916) and NPC1L1 (rs2073547), the targets of statins and ezetimibe, respectively, but it resulted also significant for the SNPs targeting PCSK9 and LDLR genes. This report analysed slight LDL-C reductions in a large number of subjects, but they were not confirmed in genetic LCS characterized by much lower LDL-C levels in very few subjects. A systematic review of literature 10 collected the published data regarding subjects with FHBL due to APOB and ANGPTL3 mutations, and it did not confirm an excess of diabetes in this FHBL cohort. Then, very low LDL-C levels in FHBL-1 carriers did not lead to an increase of diabetes prevalence. Subjects with FHBL-2, due to a mutation of ANGPTL3, 19 might be even characterized by an increase of insulin sensitivity, as demonstrated by a review of a large cohort of ANGPTL3 mutations carriers. 19 FHBL caused by severe mutations of the PCSK9 gene did not show a clear excess of diabetes, though the low number of collected cases limits the strength of the conclusion. More data are available for subjects carrying PCSK9 variants. The most investigated functional PCSK9 variant is the R46L substitution that did not show an excess of diabetes in the French cohort of the DESIRE study, 42 not confirming the data of the cited meta-analysis. 41 The second issue is the possibility that any drug lowering cholesterol levels, beyond statins, might increase the risk of diabetes. Such risk was evaluated also in patients undergoing anti-PCSK9 Mab therapy. A pooled analysis of ten ODISSEY trials was examined for early signs of IR or overt diabetes during the years of the trials observation. With the limitation of the short period of observation, no excess of diabetes was detected in more than 3000 subjects under alirocumab therapy. 43 The levels of glycated haemoglobin remained unchanged up to 78 weeks of observation and beyond, outlining that also early blood glucose modifications preceding the development of diabetes were not recorded. No systematic revision of the PROFICIO program has been produced for evolocumab in terms of risk of diabetes, but data on new onset of diabetes were available in the long-term extension of the OSLER-1 study. 44 No excess of diabetes was found in subjects undergoing evolocumab therapy in comparison with patients under standard-of-care therapy, and no increase trend was reported according to the cumulative years of exposure to evolocumab (more than 4 years total). The FOURIER trial included more than 27 000 of patients, though the trial follow-up extended for an average of 26 months. 45 There was no difference in the occurrence of new onset diabetes between the non-diabetic patients in evolocumab treatment and those in conventional therapy. Different meta-analyses have summarized the results of the anti-PCSK9-MAb trials, and results have not been consistent. A first analysis included 68 123 participants from 20 RCT followed for 78 weeks, and it showed parallel significant increases of fasting blood glucose [1.88 independent from an increase of LDLR expression, but it could be related to the PCSK9-mediated regulation of adipose tissue VLDL-receptor. 48 Visceral fat accumulation was confirmed also in human carriers of the PCSK9 R46L mutation by nuclear magnetic resonance (NMR) imaging. 49 In spite of these data, no atherogenic lipid profile occurred in R46L carriers, 50 and lipoprotein size was unaltered in comparison with controls by NMR. 50 Altogether examined, the data suggest that the increase of diabetes risk is related to the use of statins, while low cholesterol levels achieved by gene mutations, or by PCSK9 inhibitors, do not seem to cause an excess of diabetes. Figure 3 shows the possible mechanisms taken into consideration to explain the link between T2DM, LCS and lipid-lowering drugs; panels A and B show the hepatic and pancreatic mechanisms, respectively.
Low cholesterol levels and the risk of cognitive disorders
Some concerns have been expressed regarding the possibility that very low LDL-C levels might cause neurological dysfunction and cognitive impairment. Though neurocognitive disorders have not been identified as typical features of LCS 1 with the exception of ABL, a description of a kindred carrying an APOB mutation encoding for an apoB29.4 truncation reported neuro-psychiatric symptoms, with different cases of homicidal/ suicidal behaviour and aggressive attitude only in the affected members. 51 An animal model of FHBL-1 was obtained by targeting mouse APOB, resulting in a truncated apoB70. 52 This model was characterized by an excess of exencephalus and hydrocephalus that was confirmed in a homozygous apoB83 mice model. 53 Nevertheless, different homozygous FHBL cases have been reported in literature 54 and none of them reported striking brain abnormalities, pointing out the differences between human and mouse models of apoB disorders. Plasma PCSK9 reduces cholesterol interacting with LDLR, but alternative roles have been postulated for the intracellular protein. PCSK9 plays roles in glucose metabolism, in arterial plaque formation and destabilization, in response to infection, and finally in neuronal development and cognitive functions. 8 PCSK9 was initially defined as neural apoptosisregulated convertase-1 (narc1), since it was considered a modulator of neuron apoptosis and degeneration. 8 The data on PCSK9 knock-out mice did not demonstrate a clear interference with neuronal development, and other data regarding neuronal apoptosis and Alzheimer's disease (AD)-like neurocognitive disorders were not always consistent. 8 It is worth noting that no clear excess of AD-related symptoms or signs have been described in PCSK9 mutated patients. The anti-PCSK9 Mab trials did not show an excess of neurological symptoms, by considering the pooled safety analysis of evolocumab patients, 55 the safety analysis of 14 alirocumab trials, 56 and the subset of patients with the lowest LDL levels achieved by alirocumab treatment. 57 The EBBINGHAUS trial was dedicated to neurocognitive functions in 1204 patients in evolocumab 37 Decrease in isoprenoids as farnesyl pyrophosphate ( ) reduces the translocation of the GLUT4 carrier. FHBL-2 might increase insulin sensitivity by acting at receptor level, but no confirmatory data are currently available. (B) Pancreatic beta cell: The effects of the inhibition of the mevalonate pathway have been described for the hepatocyte. In the beta cell, an increase of the intracellular cholesterol (IC) pool results from increased LDLR recycling due to impaired PCSK9 function ( ). The increase of IC might stabilize glucokinase on insulin (I) granules surface resulting in insulin secretion dysfunction. 59 C, cholesterol; CellM, cell membrane; GLUT4, glucose transporter type 4; NuclearM, nuclear membrane.
Anti-PCSK9 monoclonal antibodies vs. low cholesterol syndromes treatment, and no differences in cognitive tests were observed during the 19 average month of observation. 58 In conclusion, no clear neurocognitive impairment has been observed either in the anti-PCSK9 Mab trials, or in any of the LCS genetic models considered in this review (apart from ABL). Then, a very low amount of apoB-transported cholesterol in the plasma seems sufficient to prevent the neurological alterations observed in ABL, where LDL-C is virtually absent in the plasma. Figure 4 shows the cholesterol metabolism in the brain and the cholesterol exchange between neurons and astrocytes. Possible links between LCS, lipid-lowering drugs, and cholesterol metabolism are also shown.
Conclusion
The anti-PCSK9 Mab, novel, and potent lipid-lowering drugs, have been developed and commercialized in the last years demonstrating to effectively reduce LDL-C on top of maximum tolerated statin and/or ezetimibe therapy. Anti-PCSK9 Mab therapy also demonstrated that the extreme reduction of LDL-C levels achieved was able to prevent further CV events. Few side effects emerged both during the trials observation periods, and the few marketing years of anti-PCSK9 Mab demonstrated that there is no increase in the risk of liver disease, confirming the few data drawn from the natural model of LCS due to PCSK9 gene defects.
With regard to the risk of new cases of diabetes mellitus, the data suggest that diabetes represents a side effect of the statin therapy, while these novel drugs, in concordance with the LCS models, do not show a clear excess of diabetes prevalence. Nevertheless, published data on LCS and diabetes are still controversial.
In relation to the feared effects on neurocognitive functions, both drug trials and genetic LCS models seem to rule out a possible impairment of neurological functions by anti-PCSK9 therapy.
It is important to highlight that that the LCS represent extreme models, since they reduce LDL-C levels life-long, while low levels determined by drug therapies are often discontinuous and with a broad individual variability. Then, some of the effects described in LCS might not be observed in subjects exposed to a prolonged use of these novel drugs. In spite of this limitation, the present review points out where to search for possible long-term side effects of these novel therapies, while reinforcing the need of clinical protocols for the follow-up of sensible target organs, namely the liver and the intestine. Figure 4 Cholesterol metabolism in the brain, low cholesterol syndromes and lipid-lowering drugs. Lipoproteins do not cross the bloodbrain barrier (BBB). Cholesterol (C) is mainly produced by astrocytes and travels to neurons in vesicular structures containing mainly C, phospholipids (PL), and apolipoprotein E (apoE). 60, 61 ApoE in neurons is recognized by the apoE receptor (apoE-R), which is under the control of PCSK9 as described for LDL-R. Excess of cholesterol is oxided to 24S-hydroxycholesterol ( ) by the cholesterol 24-hydroxylase (CYP46A1). The 24SOH is packed in the same vesicular structure and is recycled to astrocytes, after internalization by LDLR. Part of 24SOH can cross the BBB, being detected in the plasma. 60 ,61 FHBL due to PCSK9 defects ( ) could alter C metabolism affecting its recycling, while anti-PCSK9 MAb ( ) do not cross the BBB. Neurological features observed in ABL and homozygous FHBL are more related to lack of lipophylic vitamins than to decreased C production in the brain. ABCA1, ATP binding cassette A1.
